Want to join the conversation?
$BXLT completed the acquisition of ONCASPAR leukemia portfolio from Sigma-Tau Finanziaria. This acquisition includes ONCASPAR, a biologic treatment for acute lymphocytic leukemia (ALL), the investigational biologic calaspargase pegol, and an established oncology infrastructure with clinical and sales resources.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.